Shopping Cart 0
Cart Subtotal
AED 0

Takeda Pharmaceutical Co Ltd (4502) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Takeda Pharmaceutical Company Ltd (Takeda) is a research-based global pharmaceutical company which focuses on the research and development, manufacture, marketing, commercialization and import and export of pharmaceutical drugs and consumer health care products. The company manufactures and markets a wide range of products including photographic chemicals, inorganic chemicals, vitamin bulks, test reagents and clinical diagnostics. Takeda markets its drugs worldwide through its subsidiaries in North America, Europe and Asia. It operates production facilities in Osaka and Hikari in Japan; Italy; Ireland; Germany; Austria; Denmark; Belgium; Norway; Poland; Russia; China; Indonesia; Mexico; Brazil; Argentina; Columbia; Estonia; and India. It also operates research and development facilities at various locations in Japan and the US, China and the UK; and in Brazil, Germany, Switzerland, and Singapore. Takeda is headquartered in Chuo-ku, Osaka, Japan.

Takeda Pharmaceutical Co Ltd (4502)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 10

List of Figures 15

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 16

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 17

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 18

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 19

Takeda Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 21

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 22

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 44

Asset Purchase 44

Takeda Pharma Acquires Biologics Manufacturing Facility from Baxalta 44

Venture Financing 45

VelosBio Raises USD58 Million in Series A Financing 45

Ambys Medicines Raises USD60 Million in Series A Venture Financing 46

StrideBio Raises USD15.7 Million in Series A Financing 47

Cortexyme Raises USD76 Million in Series B Venture Financing 48

Crescendo Biologics Raises USD69.1 Million in Series B Venture Financing 50

Univercells Raises USD3.5 Million in Series A2 Financing 52

Hookipa Biotech Raises USD58.8 Million in Series C Financing 53

Obsidian Therapeutics Raises USD49.5 Million in Series A Financing 55

Chordia Therapeutics Raises Funds in Series A Financing 56

TiGenix Raises USD0.02 Million in Venture Financing 57

Outpost Medicine Raises Additional USD20 Million in Series A Financing 58

Palleon Pharma Raises USD47.6 Million in Series A Financing 59

OrphoMed Raises USD39 Million in Series A Financing 60

Biomx Raises USD24 Million in Series A Venture Financing 61

Avidity Biosciences Raises USD10 Million in Series B Venture Financing 63

Cerevance Raises USD21.5 Million in Series A Financing 65

Bioniz Therapeutics Raises USD13 Million in Series A Venture Financing 66

Mersana Therapeutics Raises USD33 Million in Series C Financing Round 67

Cortexyme Raises USD15 Million in Series A Financing Round 69

Protekt Therapeutics Raises More Than USD2 Million in Financing 70

Univercells Raises USD3.4 Million in Equity Financing Round 71

Encycle Therapeutics Raises USD2 Million in Seed Financing 72

Presage Biosciences Raises Funds through Venture Financing 73

Naurex Raises USD80 Million in Series C Venture Financing 74

Naurex Raises USD 25 Million In Venture Financing 76

VHsquared Secures Series A Funding Round 78

Hookipa Biotech Raises USD 27 Million In Series B Financing 79

TiGenix Raises USD8.5 Million in Venture Financing 81

Heptares Therapeutics Raises USD 21 Million In Series B Financing 82

Redwood Bioscience Raises USD 8.6 Million In Venture Financing 83

Naurex Raises USD 38 Million In Series B Financing 84

ArmaGen Technologies Raises USD 17 Million In Series A Financing 86

Juventas Therapeutics Raises USD 22.2 Million In Series B Venture Financing Round 88

LigoCyte Pharmaceuticals Raises USD 2 Million In Venture Financing Round 90

Private Equity 91

Valeant Pharma Rejects Joint Takeover Bid from Takeda Pharma and TPG Capital Management 91

Sarissa Capital Acquires 6.22% Stake In Ariad Pharma 92

Partnerships 93

Molecular Templates Enters into Agreement with Takeda Pharma 93

Ambys Medicines and Takeda Pharma Enter into Partnership Agreement 94

HiFiBiO Therapeutics Enters into Agreement with Takeda Pharma 95

leon-nanodrugs Enters into Agreement with Takeda Pharma 96

HaemaLogiX Enters into Research Collaboration Agreement Takeda Pharma 97

Nektar Therapeutics Enters into Clinical Collaboration with Takeda Pharma 98

Takeda Pharma Enters into Agreement with DNDi 99

Beacon Discovery Enters into Drug Discovery Agreement with Takeda Pharma 100

Fujifilm and Takeda Pharma Enter into Agreement 101

Takeda Pharma and Denali Therapeutics to Enter into Agreement 102

Takeda Pharma and Montreal Neurological Institute and Hospital Enter into Research Partnership 103

Takeda Pharma and Portal Instruments Enter into Agreement 104

Takeda Pharma and HemoShear Therapeutics Enter into Agreement 105

Recursion Pharma Enters into Agreement with Takeda Pharma 106

Takeda Pharma, Karolinska Institutet and Structural Genomics Consortium Enter into Agreement 107

HitGen Enters into Agreement with Takeda Pharma 108

Millennium Pharma and Noile-Immune Biotech Enter into Agreement 109

AstraZeneca and Takeda Pharma Enter into Co-Development Agreement 110

Samsung Bioepis Enters into Co-Development Agreement with Takeda Pharma 111

Millennium Pharma and Shattuck Labs Enter into Research Agreement 112

Takeda Pharma Partners with Stanford University 113

Takeda Pharma Enters into Research Agreement with Molecular Templates 114

Takeda Pharma and Cardurion Pharma Enter into Partnership 115

Takeda Pharma and Schrodinger Enter into Research Partnership 116

Prana Biotech Enters into Research Agreement with Takeda Pharma 117

Heidelberg Pharma Enters into Research Agreement with Takeda Pharma 118

Numerate Enters into Agreement with Takeda Pharma 119

Nektar Therapeutics Enters into Agreement with Takeda Pharma 120

Takeda Pharma and GammaDelta Therapeutics Enter into Partnership 121

Takeda Pharma and Harrington Discovery Institute Enter into Partnership 122

Takeda Pharma Enters into Agreement with NuBiyota 123

PRA Health Sciences and Takeda Pharma Form Joint Venture 124

Center for iPS Cell Research and Application, Takeda Pharma and RIKEN Enter into Partnership 125

INCJ, Takeda Pharma and MediPal Holdings Form Joint Venture 126

Innovation Network Corporation of Japan, Takeda Pharma and MEDIPAL HOLDINGS Enter into Partnership 127

Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 128

Takeda Pharma Enters into Agreement with Maverick Therapeutics 130

Takeda Pharma and Ovid Therapeutics Enter into Agreement 131

Takeda Pharma Enters into Development Agreement wtih PvP Biologics 133

Arcturus Therapeutics Extends Agreement with Takeda Pharma 134

CiRA, Takeda Pharma and Yokohama City University Enter into Research Agreement 135

EnGeneIC Enters into Agreement with Millennium Pharma 136

Takeda Pharma Enters into Agreement with Affilogic 137

Zydus Cadila Healthcare Enters into Agreement with Takeda Pharma 138

PRA Health Sciences Enters into Agreement with Takeda Pharma 139

Biomedical Advanced Research and Development Authority Enters into Agreement with Takeda Pharma 140

TB Alliance and Takeda Pharma Enter into Agreement 141

Ariad Pharma Enters into Distribution Agreement with Pint Pharma International 142

Ariad Pharma Enters into Distribution Agreement with Biologix 143

Takeda Pharma Enters into Agreement with M2Gen 144

Takeda Pharma Forms Joint Venture with Roivant Sciences 145

Takeda Pharma Enters into Co-Development Agreement with Ultragenyx Pharma 146

Astellas Pharma, Daiichi Sankyo and Takeda Pharma Enter into Research Agreement 147

Prosetta Biosciences Enters into Agreement with Takeda Pharma 148

Adimab Enters into Drug Discovery Agreement with Takeda Pharma 149

RaQualia Pharma Enters into Agreement with Takeda Pharma 150

TiGenix Forms Partnership with TFS International 151

Teva Pharma and Takeda Pharma Form Joint Venture 152

Takeda Pharma Enters into Research Agreement with University of Chicago and Icahn School of Medicine at Mount Sinai 154

Broad Institute Genomic Services Partners with Takeda Pharma 155

Takeda Pharma Enters into Partnership with enGene 156

Takeda Pharma Enters into Agreement with Enterome Bioscience 157

Vipergen Enters into Agreement with Takeda Pharma 158

Center for iPS Cell Research and Application Enters into Agreement with Takeda Pharma 159

Takeda Pharma Enters into R&D Agreement with Cour Pharma 160

University College London Enters into Research Agreement with Takeda Pharma 161

Takeda Pharma Enters into Agreement with Nanotherapeutics 162

DNDi Enters into Agreement with Takeda Pharma 163

ARIAD Pharma Enters into Distribution Agreement with Paladin 164

Takeda Pharma Enters into Agreement with Sanford-Burnham 165

National Cancer Center and Takeda Pharma to Develop Anti-Cancer Agents 166

Ariad Pharma Enters into Distribution Agreement with GEN Ilac 167

Takeda Enters into Research Agreement with Keio University School of Medicine and Niigata University 168

CiRA Enters into Co-Development Agreement with Takeda Pharma 169

BioXcel Enters into Agreement with Takeda Development Center Americas 170

Queen Mary University of London Enters into Research Agreement with Takeda Pharma 171

Prasco Lab Enters into Co-Marketing Agreement with Takeda Pharma 172

Ariad Pharma Enters into Co-Marketing Agreement with Angelini Pharma for Iclusig 173

Ariad Pharma Enters into Co-Marketing Agreement with Otsuka Pharma for Iclusig 174

Monash Institute and Monash University Enter into Research Agreement with Takeda Pharma 176

Presage Biosciences Expands its Research Agreement with Takeda Pharma 177

GE Healthcare Enters into R&D Agreement with Takeda Pharma 178

GVK Biosciences Forms Joint Venture with Takeda Pharma 179

MacroGenics Enters into Co-Development Agreement with Takeda Pharma 180

Meiji Seika Pharma Enters into Co-Promotion Agreement with Takeda Pharma for Rozerem 181

Takeda Pharma Enters Option Agreement with MacroGenics for MGD010 182

Pantec Biosolutions Enters into Research Agreement with Takeda Pharma 184

Teva Pharma Enters Into Agreement With Takeda Pharma To Commercialize Rasagiline In Japan 185

Mersana Therapeutics Expands Agreement with Takeda Pharma 186

Mersana Expands Co-Development Agreement with Takeda Pharma 187

Otsuka Enters Into Co-Promotion Agreement With Takeda For TAK-438 188

Takeda Enters into R&D Agreement with University College London 190

Ariad Pharma Enters Into Agreement With Specialised Therapeutics To Commercialize Iclusig In Australia 191

Takeda Pharma Enters Into Co-Marketing Agreement With Research Foundation For Microbial Diseases Of Osaka University 192

OrbiMed Israel Partners, JJDC and Takeda Ventures Form Joint Venture 193

Takeda Pharma Enters into Agreement with Medicines for Malaria Venture 194

TiGenix To Enter Into Co-Marketing Agreement For Cx601 195

Tri-Institutional Therapeutics Expands Agreement with Takeda Pharma 196

Takeda Nycomed Enters Into Co-Marketing Agreement With Shire For Calcichew D3 Portfolio 197

Takeda Pharma Enters Into Co-Promotion Agreement With Sanofi For Alogliptin 198

Interprotein Enters Into Agreement With Takeda Pharma For PPI Inhibitors 199

Scripps Research Institute Expands Research Agreement With Takeda 200

Takeda Pharma Enters Into Co-Development Agreement With Resolve Therapeutics 201

Sanford-Burnham And Florida Hospital Extend Research Agreement With Takeda 202

Gladstone Enters into Research Agreement with Takeda Pharma 204

Hyundai Pharma Enters into Distribution Agreement with Takeda Pharma for TachoSil 205

Takeda Pharma Enters Into Drug Discovery Agreement With Advinus Therapeutics 206

Takeda Pharma Enters Into Distribution Agreement With Johnson & Johnson For Seven OTC Brands 207

Jeil Pharma Enters Into Distribution Agreement With Takeda Pharma For Dexilant 208

Riken Enters Into Agreement With Takeda Pharma To Form Riken Bsi-Takeda Collaboration Center 209

Metabolon Enters Into Co-Development Agreement With Takeda Pharma 210

Seattle Genetics And Millennium Pharma Enter Into Co-Development Agreement With Ventana Medical Systems 211

Presage Biosciences Enters Into Co-Development Agreement With Millennium Pharma For Cancer Drugs 213

Affymax Enters Into Co-Promotion Agreement With Takeda For Peginesatide 214

CIC bioGUNE Enters into Agreement with Millennium Pharma 215

Takeda Pharma Enters Into Research Agreement With Osaka University 216

Licensing Agreements 217

Takeda Pharma Exercises Option for Licensing Agreement with Crescendo Biologics 217

Takeda Pharma Enters into Licensing Agreement with Enterome 218

ASKA Pharma Enters into Licensing Agreement with Takeda Pharma 219

FIMECS Enters into Licensing Agreement with Takeda Pharma 220

Rhythm Pharma Enters into Licensing Agreement with Takeda Pharma 221

Takeda Pharma to Enter into Licensing Agreement with Wave Life Sciences 222

Mesoblast Enters into Licensing Agreement with TiGenix 224

Izana Bioscience Enters into Licensing Agreement with Takeda Pharma 225

Hikma Pharma Enters into Licensing Agreement with Takeda Pharma for Dexilant 226

Hikma Pharma Expands Licensing Agreement with Takeda Pharma for Xefo 227

Hikma Pharma Enters into Licensing Agreement with Takeda Pharma for Vipedia and Edarbi 228

Takeda Pharma Enters into Licensing Agreement with Isogenica for llamdA 229

Millennium Pharma Enters into Licensing Agreement with Tesaro 230

Takeda Pharma Enters into Licensing Agreement with Selexis 231

Biological E Enters into Licensing Agreement with Takeda Pharma 232

Takeda Pharma Enters into Licensing Agreement with Finch Therapeutics 233

Katairo Enters into Licensing Agreement with Takeda Pharma 234

Takeda Pharma Enters into Licensing Agreement with Exelixis 235

Millennium Pharma Enters into Licensing Agreement with LegoChem Biosciences 236

Teva Pharma Enters into Licensing Agreement with Takeda for Attenukine 237

Takeda Pharma Enters into Licensing Agreement with TiGenix for Cx601 238

Teva Pharma Enters into Licensing Agreement with Takeda Pharma for Ninlaro 240

Takeda Pharma Enters into Licensing Agreement with Theravance Biopharma for TD-8954 241

Dermira Enters into Option Agreement with Takeda Pharma 242

Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for Relugolix 243

Incyte Amends Licensing Agreement with ARIAD Pharma 244

Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for RVT-602 245

Outpost Medicine Enters into Licensing Agreement with Takeda Pharma 246

Takeda Pharma Enters into Licensing Agreement with Gencia 247

Takeda Enters into Licensing Agreement with ImmunoGen 248

Takeda Enters into Licensing Agreement with Kaketsuken for Human Papillomavirus Vaccine 249

Mersana Exercises Option for License Agreement with Millennium 250

Sucampo Pharma Enters Into Licensing Agreement with Takeda Pharma 251

Takeda and Aska Pharma Enter into Licensing Agreement for Candesartan Aska 253

TiGenix Enters Licensing Agreement With Sobi for ChondroCelect 254

Sunesis Pharma Enters Into Licensing Agreement With Millennium Pharma 255

Takeda Pharma Enters Into Licensing Agreement With Arbor Pharma For Edarbi And Edarbyclor 256

NPS Pharma Enters Into Licensing Agreement With Takeda Pharma For Teduglutide And PTH 1-84 257

Apricus Biosciences Enters Into Licensing Agreement With Takeda Pharma For Vitaros 258

Takeda Pharma Enters into Licensing Agreement with Kaketsuken 259

Valeant Canada Enters into Licensing Agreement with Takeda Pharma for Edarbi and Edarbyclor 260

Takeda And Trianni Enter Into Licensing Agreement For Trianni Transgenic Mouse Platform 261

Takeda Pharma Enters Into Licensing Agreement With Natrogen Therapeutics For Inflammatory Bowel Disease 262

Teva Pharma Enters Into Licensing Agreement With Takeda Pharma For Glatiramer Acetate 263

Takeda California Enters Into Licensing Agreement With Sea Lane Biotech For ConCIRT Libraries and Technology 264

Daewoong Pharma Enters Into Licensing Agreement With Takeda Pharma For Instanyl 265

Takeda Expands Licensing Agreement With Genedata For Genedata Expressionist 266

Equity Offering 267

Reborna Biosciences Raises USD2.3 Million in Private Placement of Shares 267

Infinity Pharma Plans to Raise USD2.5 Million in Public Offering of Shares 268

Arix Bioscience to Raise USD76.7 Million in Private Placement of Shares 269

Chordia Therapeutics Spin Out from Takeda Pharma 271

Molecular Templates Raises USD20 million in Equity Financing 272

TiGenix Raises USD35.7 Million in Public Offering of ADS 273

TiGenix to Raise USD10.4 Million in Private Placement of Shares 275

Ultragenyx Pharma Raises up to USD65 Million in Private Placement of Shares 276

TiGenix Raises USD26 Million in Private Placement of Shares 278

Aquinnah Pharma Raises USD5 Million in Private Placement of Shares 279

Prosetta Biosciences Raises USD31 Million in Series D Private Placement 280

TiGenix Raises USD9.2 Million in Private Placement of Shares 281

TiGenix Completes Private Placement Of Shares For USD 16.2 Million 282

TiGenix Completes Private Placement Of Shares For USD 8.5 Million 283

Ariad Pharma Completes Public Offering Of Common Stock For USD 323 Million 284

TiGenix Completes Private Placement Of Shares For USD 9 Million 286

Debt Offering 287

Takeda Pharma to Raise up to USD20 Billion in Private Placement of Bonds 287

Takeda Pharma Raises USD500 Million in Private Placement of 2.45% Notes Due 2022 288

TiGenix Raises USD28.3 Million in Private Placement of 9% Bonds Due 2018 289

Ariad Pharma Raises USD200 Million in Private Placement of 3.625% Notes Due 2019 290

TiGenix Announces Private Placement Of Debt Securities For USD 13.7 Million 291

Takeda Pharma Completes Public Offering Of Fourteenth Series Bonds Due 2019 For USD 593.5 Million 292

Takeda Pharma Completes Public Offering Of Fifteenth Series Bonds Due 2020 For USD 593.5 Million 293

Takeda Pharma Completes Private Placement Of Notes Due 2015 For USD 1,500 Million 294

Takeda Pharma Completes Private Placement Of Notes Due 2017 For USD 1,500 Million 295

Takeda Pharma Completes Public Offering Of Eleventh Series Bonds Due 2016 For USD 870 Million 296

Takeda Pharma Completes Public Offering Of Twelfth Series Bonds Due 2017 For USD 745 Million 297

Takeda Pharma Completes Public Offering Of Thirteenth Series Bonds Due 2018 For USD 745 Million 298

Asset Transactions 299

Takeda Pharma May Sell Shire's Ophthalmology Products 299

Chinoin Pharma Acquires Colombian Production Unit from Takeda Pharma 300

Takeda Pharma Plans to Sell Additional Products to Teva Takeda Yakuhin for USD256.5 Million 301

Acino International Acquires Manufacturing Business from Takeda Pharma 302

AstraZeneca Acquires Core Respiratory Business from Takeda Pharmaceutical for USD575 Million 303

Fraunhofer ITEM Acquires Surfactant and CPA Program Assets from Takeda 304

PDL BioPharma Acquires Royalty Revenue of Iclusig from ARIAD Pharma for USD200 Million 305

Infinity Pharma Exercises Option to Acquire Duvelisib Royalty Rights from Takeda Pharma 307

Dr. Kade Pharma Acquires Portfolio Of OTC Products From Takeda 308

Caraco Pharma Completes Acquisition Of Non-Colcrys Business Of URL Pharma From Takeda Pharma For USD 65 Million 309

Acquisition 310

Takeda Pharma Acquires TiGenix for USD626.4 Million 310

Shanghai Pharma to Acquire 26.34% Stake in Techpool Bio-Pharma from Takeda Pharma for USD143.4 Million 312

Sunrise Bright to Acquire 25% Stake in Techpool Bio-Pharma from Takeda Pharma for USD135.8 Million 313

Takeda Pharma to Acquire Shire 314

Novamed Fabricacao de Produtos Farmaceuticos Acquires Multilab Industria e Comercio de Produtos Farmaceuticos from Takeda Pharma 317

Johnson & Johnson, Novartis and Takeda Pharma May Acquire Hypermarcas 318

Takeda Acquires Altos Therapeutics 320

Takeda Pharma Acquires Ariad Pharma for up to USD5.2 Billion in Tender Offer 321

Takeda Pharma May Acquire Salix Pharma for up to USD10 Billion 323

Incyte Acquires ARIAD Pharma (Luxembourg) for USD140 Million 324

TiGenix Acquires Coretherapix from Genetrix 326

Takeda to Acquire Neutec Total from Neutec for up to USD121 Million 327

Takeda Pharma Acquires Minority Stake in BioMotiv for USD25 Million 328

PharmaCell Completes Acquisition of TiGenix, Operator of Cell Therapy Production Facility in Netherlands for USD7.8 Million 329

AstraZeneca May Acquire Ariad Pharma 330

Takeda America Completes Acquisition Of Inviragen For USD 250 Million 332

Takeda Completes Acquisition Of Remaining 87.5% Stake In Envoy Therapeutics For Up To USD 140 Million 334

Takeda America Completes Acquisition Of LigoCyte Pharma For USD 60 Million 336

Takeda Pharma Invests USD 5 Million In Advinus Therapeutics 338

Takeda Completes Acquisition Of Multilab, Brazilian Drugmaker, For Up To USD 265 Million 339

Takeda America Completes Acquisition Of URL Pharma For USD 800 Million 341

Takeda Completes Acquisition Of Intellikine For USD 310 Million 343

Takeda Pharmaceutical Co Ltd - Key Competitors 345

Takeda Pharmaceutical Co Ltd - Key Employees 346

Takeda Pharmaceutical Co Ltd - Locations And Subsidiaries 347

Head Office 347

Other Locations & Subsidiaries 347

Joint Venture 354

Recent Developments 356

Strategy And Business Planning 356

Sep 21, 2018: Takeda and Molecular Templates partner on protein-based cancer therapy 356

Aug 10, 2018: Ambys Medicines and Takeda to develop new therapies for liver diseases 357

Oct 01, 2017: ChromaJean to Launch at Takeda's Shonan Research Center 358

Jul 31, 2017: SEEDSUPPLY to Launch at Takedas Shonan Research Center 359

Jul 10, 2017: Takeda Announces the Start of Operations for AXCELEAD at its Shonan Research Center 360

Jun 16, 2017: Takeda Announces Completion of New Manufacturing Facilities at the Oranienburg Site in Germany 361

May 15, 2017: Takeda Announces Establishment of its Wholly-owned Subsidiary at Shonan Research Center which Supports Drug Discovery to Drive Innovation 362

Apr 03, 2017: Takeda Consumer Healthcare Company starts its business 363

Feb 20, 2017: Takeda Announces Further Details of Splitting off (Simple Absorption-type Split) of Japan Consumer Healthcare Business Unit 364

Financial Announcements 366

Oct 31, 2018: Takeda reports second quarter FY2018 results 366

Jul 31, 2018: Takeda reports first quarter financial result 2018 results 368

May 14, 2018: Takeda reports FY2017 full year results and issues FY2018 guidance 370

Feb 01, 2018: Takeda Reports 3rd Quarter FY2017 Results 372

Nov 01, 2017: Takeda Reports First Half FY2017 Results 373

Jul 27, 2017: Takeda reports 1st Quarter FY2017 results 374

May 10, 2017: Takeda reports FY2016 full year results and issues FY2017 guidance 375

Feb 01, 2017: Takeda reports Q3 FY2016 results and improves year-end outlook 376

Corporate Communications 377

Mar 08, 2018: Takeda Announces Resignation of James Kehoe and Appointment of Costa Saroukos as CFO 377

Mar 30, 2017: Takeda Announces Ricardo Marek as New President of Emerging Markets Business Unit 378

Government and Public Interest 379

Jul 09, 2018: Takeda Announces Selection of Three New Programs for Global Corporate Social Responsibility CSR Program 2018 Promoting Disease Prevention to Improve Health in Developing and Emerging Countries 379

Jun 07, 2018: Takeda pioneers NICEs new service for economic model review 381

Jul 27, 2017: Takeda selected by major index and sustainability rating institutions concerning Corporate Social Responsibility 382

Jun 30, 2017: Takeda Announces Selection of Global CSR Programs Emphasizing Prevention for Health in Developing and Emerging Countries 383

Feb 08, 2017: Takeda Presents $1 Million Gift to the Koch Institute for Integrative Cancer Research at MIT to Support Immuno-oncology Research 384

Product News 385

06/22/2017: NICE approves COPD treatment roflumilast for routine NHS use 385

Product Approvals 386

Sep 11, 2017: AstraZenecas Daxas Rejects For Use Within NHS Scotland 386

Apr 28, 2017: NICE issues ponatinib recommendation 387

Clinical Trials 388

Aug 13, 2018: Samsung Bioepis to begin Phase l trial of SB26 for pancreatitis 388

Mar 22, 2018: Takeda Announces Publication of Final Data from ICLUSIG (ponatinib) Pivotal Phase 2 PACE Trial in Blood 389

Nov 01, 2017: Data To Be Presented On ICLUSIG (ponatinib) During 59th American Society of Hematology Annual Meeting 391

Nov 01, 2017: Incyte Presents Ponatinib Data at 59th Annual ASH Meeting 392

Other Significant Developments 393

Aug 15, 2018: Crescendo Biologics reaches technical milestone for a second target in strategic collaboration with Takeda 393

Jul 02, 2018: Takeda Global Headquarters Grand Opening 394

Mar 20, 2018: Completion of Takeda Global Headquarters 395

Nov 10, 2017: Takeda Supports Launch of Five-Year, $1M Initiative Spearheaded by the Massachusetts Life Sciences Center to Back Women-Driven Early Stage Companies 396

Mar 13, 2017: INCJ, Takeda, and MEDIPAL HOLDINGS Partner to Launch a Biotech Venture 397

Appendix 398

Methodology 398

About GlobalData 398

Contact Us 398

Disclaimer 398


List Of Figure

List of Figures

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 16

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 17

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 18

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 19

Takeda Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 21


List Of Table

List of Tables

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 16

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 17

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 18

Takeda Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 19

Takeda Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 21

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 22

Takeda Pharma Acquires Biologics Manufacturing Facility from Baxalta 44

VelosBio Raises USD58 Million in Series A Financing 45

Ambys Medicines Raises USD60 Million in Series A Venture Financing 46

StrideBio Raises USD15.7 Million in Series A Financing 47

Cortexyme Raises USD76 Million in Series B Venture Financing 48

Crescendo Biologics Raises USD69.1 Million in Series B Venture Financing 50

Univercells Raises USD3.5 Million in Series A2 Financing 52

Hookipa Biotech Raises USD58.8 Million in Series C Financing 53

Obsidian Therapeutics Raises USD49.5 Million in Series A Financing 55

Chordia Therapeutics Raises Funds in Series A Financing 56

TiGenix Raises USD0.02 Million in Venture Financing 57

Outpost Medicine Raises Additional USD20 Million in Series A Financing 58

Palleon Pharma Raises USD47.6 Million in Series A Financing 59

OrphoMed Raises USD39 Million in Series A Financing 60

Biomx Raises USD24 Million in Series A Venture Financing 61

Avidity Biosciences Raises USD10 Million in Series B Venture Financing 63

Cerevance Raises USD21.5 Million in Series A Financing 65

Bioniz Therapeutics Raises USD13 Million in Series A Venture Financing 66

Mersana Therapeutics Raises USD33 Million in Series C Financing Round 67

Cortexyme Raises USD15 Million in Series A Financing Round 69

Protekt Therapeutics Raises More Than USD2 Million in Financing 70

Univercells Raises USD3.4 Million in Equity Financing Round 71

Encycle Therapeutics Raises USD2 Million in Seed Financing 72

Presage Biosciences Raises Funds through Venture Financing 73

Naurex Raises USD80 Million in Series C Venture Financing 74

Naurex Raises USD 25 Million In Venture Financing 76

VHsquared Secures Series A Funding Round 78

Hookipa Biotech Raises USD 27 Million In Series B Financing 79

TiGenix Raises USD8.5 Million in Venture Financing 81

Heptares Therapeutics Raises USD 21 Million In Series B Financing 82

Redwood Bioscience Raises USD 8.6 Million In Venture Financing 83

Naurex Raises USD 38 Million In Series B Financing 84

ArmaGen Technologies Raises USD 17 Million In Series A Financing 86

Juventas Therapeutics Raises USD 22.2 Million In Series B Venture Financing Round 88

LigoCyte Pharmaceuticals Raises USD 2 Million In Venture Financing Round 90

Valeant Pharma Rejects Joint Takeover Bid from Takeda Pharma and TPG Capital Management 91

Sarissa Capital Acquires 6.22% Stake In Ariad Pharma 92

Molecular Templates Enters into Agreement with Takeda Pharma 93

Ambys Medicines and Takeda Pharma Enter into Partnership Agreement 94

HiFiBiO Therapeutics Enters into Agreement with Takeda Pharma 95

leon-nanodrugs Enters into Agreement with Takeda Pharma 96

HaemaLogiX Enters into Research Collaboration Agreement Takeda Pharma 97

Nektar Therapeutics Enters into Clinical Collaboration with Takeda Pharma 98

Takeda Pharma Enters into Agreement with DNDi 99

Beacon Discovery Enters into Drug Discovery Agreement with Takeda Pharma 100

Fujifilm and Takeda Pharma Enter into Agreement 101

Takeda Pharma and Denali Therapeutics to Enter into Agreement 102

Takeda Pharma and Montreal Neurological Institute and Hospital Enter into Research Partnership 103

Takeda Pharma and Portal Instruments Enter into Agreement 104

Takeda Pharma and HemoShear Therapeutics Enter into Agreement 105

Recursion Pharma Enters into Agreement with Takeda Pharma 106

Takeda Pharma, Karolinska Institutet and Structural Genomics Consortium Enter into Agreement 107

HitGen Enters into Agreement with Takeda Pharma 108

Millennium Pharma and Noile-Immune Biotech Enter into Agreement 109

AstraZeneca and Takeda Pharma Enter into Co-Development Agreement 110

Samsung Bioepis Enters into Co-Development Agreement with Takeda Pharma 111

Millennium Pharma and Shattuck Labs Enter into Research Agreement 112

Takeda Pharma Partners with Stanford University 113

Takeda Pharma Enters into Research Agreement with Molecular Templates 114

Takeda Pharma and Cardurion Pharma Enter into Partnership 115

Takeda Pharma and Schrodinger Enter into Research Partnership 116

Prana Biotech Enters into Research Agreement with Takeda Pharma 117

Heidelberg Pharma Enters into Research Agreement with Takeda Pharma 118

Numerate Enters into Agreement with Takeda Pharma 119

Nektar Therapeutics Enters into Agreement with Takeda Pharma 120

Takeda Pharma and GammaDelta Therapeutics Enter into Partnership 121

Takeda Pharma and Harrington Discovery Institute Enter into Partnership 122

Takeda Pharma Enters into Agreement with NuBiyota 123

PRA Health Sciences and Takeda Pharma Form Joint Venture 124

Center for iPS Cell Research and Application, Takeda Pharma and RIKEN Enter into Partnership 125

INCJ, Takeda Pharma and MediPal Holdings Form Joint Venture 126

Innovation Network Corporation of Japan, Takeda Pharma and MEDIPAL HOLDINGS Enter into Partnership 127

Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 128

Takeda Pharma Enters into Agreement with Maverick Therapeutics 130

Takeda Pharma and Ovid Therapeutics Enter into Agreement 131

Takeda Pharma Enters into Development Agreement wtih PvP Biologics 133

Arcturus Therapeutics Extends Agreement with Takeda Pharma 134

CiRA, Takeda Pharma and Yokohama City University Enter into Research Agreement 135

EnGeneIC Enters into Agreement with Millennium Pharma 136

Takeda Pharma Enters into Agreement with Affilogic 137

Zydus Cadila Healthcare Enters into Agreement with Takeda Pharma 138

PRA Health Sciences Enters into Agreement with Takeda Pharma 139

Biomedical Advanced Research and Development Authority Enters into Agreement with Takeda Pharma 140

TB Alliance and Takeda Pharma Enter into Agreement 141

Ariad Pharma Enters into Distribution Agreement with Pint Pharma International 142

Ariad Pharma Enters into Distribution Agreement with Biologix 143

Takeda Pharma Enters into Agreement with M2Gen 144

Takeda Pharma Forms Joint Venture with Roivant Sciences 145

Takeda Pharma Enters into Co-Development Agreement with Ultragenyx Pharma 146

Astellas Pharma, Daiichi Sankyo and Takeda Pharma Enter into Research Agreement 147

Prosetta Biosciences Enters into Agreement with Takeda Pharma 148

Adimab Enters into Drug Discovery Agreement with Takeda Pharma 149

RaQualia Pharma Enters into Agreement with Takeda Pharma 150

TiGenix Forms Partnership with TFS International 151

Teva Pharma and Takeda Pharma Form Joint Venture 152

Takeda Pharma Enters into Research Agreement with University of Chicago and Icahn School of Medicine at Mount Sinai 154

Broad Institute Genomic Services Partners with Takeda Pharma 155

Takeda Pharma Enters into Partnership with enGene 156

Takeda Pharma Enters into Agreement with Enterome Bioscience 157

Vipergen Enters into Agreement with Takeda Pharma 158

Center for iPS Cell Research and Application Enters into Agreement with Takeda Pharma 159

Takeda Pharma Enters into R&D Agreement with Cour Pharma 160

University College London Enters into Research Agreement with Takeda Pharma 161

Takeda Pharma Enters into Agreement with Nanotherapeutics 162

DNDi Enters into Agreement with Takeda Pharma 163

ARIAD Pharma Enters into Distribution Agreement with Paladin 164

Takeda Pharma Enters into Agreement with Sanford-Burnham 165

National Cancer Center and Takeda Pharma to Develop Anti-Cancer Agents 166

Ariad Pharma Enters into Distribution Agreement with GEN Ilac 167

Takeda Enters into Research Agreement with Keio University School of Medicine and Niigata University 168

CiRA Enters into Co-Development Agreement with Takeda Pharma 169

BioXcel Enters into Agreement with Takeda Development Center Americas 170

Queen Mary University of London Enters into Research Agreement with Takeda Pharma 171

Prasco Lab Enters into Co-Marketing Agreement with Takeda Pharma 172

Ariad Pharma Enters into Co-Marketing Agreement with Angelini Pharma for Iclusig 173

Ariad Pharma Enters into Co-Marketing Agreement with Otsuka Pharma for Iclusig 174

Monash Institute and Monash University Enter into Research Agreement with Takeda Pharma 176

Presage Biosciences Expands its Research Agreement with Takeda Pharma 177

GE Healthcare Enters into R&D Agreement with Takeda Pharma 178

GVK Biosciences Forms Joint Venture with Takeda Pharma 179

MacroGenics Enters into Co-Development Agreement with Takeda Pharma 180

Meiji Seika Pharma Enters into Co-Promotion Agreement with Takeda Pharma for Rozerem 181

Takeda Pharma Enters Option Agreement with MacroGenics for MGD010 182

Pantec Biosolutions Enters into Research Agreement with Takeda Pharma 184

Teva Pharma Enters Into Agreement With Takeda Pharma To Commercialize Rasagiline In Japan 185

Mersana Therapeutics Expands Agreement with Takeda Pharma 186

Mersana Expands Co-Development Agreement with Takeda Pharma 187

Otsuka Enters Into Co-Promotion Agreement With Takeda For TAK-438 188

Takeda Enters into R&D Agreement with University College London 190

Ariad Pharma Enters Into Agreement With Specialised Therapeutics To Commercialize Iclusig In Australia 191

Takeda Pharma Enters Into Co-Marketing Agreement With Research Foundation For Microbial Diseases Of Osaka University 192

OrbiMed Israel Partners, JJDC and Takeda Ventures Form Joint Venture 193

Takeda Pharma Enters into Agreement with Medicines for Malaria Venture 194

TiGenix To Enter Into Co-Marketing Agreement For Cx601 195

Tri-Institutional Therapeutics Expands Agreement with Takeda Pharma 196

Takeda Nycomed Enters Into Co-Marketing Agreement With Shire For Calcichew D3 Portfolio 197

Takeda Pharma Enters Into Co-Promotion Agreement With Sanofi For Alogliptin 198

Interprotein Enters Into Agreement With Takeda Pharma For PPI Inhibitors 199

Scripps Research Institute Expands Research Agreement With Takeda 200

Takeda Pharma Enters Into Co-Development Agreement With Resolve Therapeutics 201

Sanford-Burnham And Florida Hospital Extend Research Agreement With Takeda 202

Gladstone Enters into Research Agreement with Takeda Pharma 204

Hyundai Pharma Enters into Distribution Agreement with Takeda Pharma for TachoSil 205

Takeda Pharma Enters Into Drug Discovery Agreement With Advinus Therapeutics 206

Takeda Pharma Enters Into Distribution Agreement With Johnson & Johnson For Seven OTC Brands 207

Jeil Pharma Enters Into Distribution Agreement With Takeda Pharma For Dexilant 208

Riken Enters Into Agreement With Takeda Pharma To Form Riken Bsi-Takeda Collaboration Center 209

Metabolon Enters Into Co-Development Agreement With Takeda Pharma 210

Seattle Genetics And Millennium Pharma Enter Into Co-Development Agreement With Ventana Medical Systems 211

Presage Biosciences Enters Into Co-Development Agreement With Millennium Pharma For Cancer Drugs 213

Affymax Enters Into Co-Promotion Agreement With Takeda For Peginesatide 214

CIC bioGUNE Enters into Agreement with Millennium Pharma 215

Takeda Pharma Enters Into Research Agreement With Osaka University 216

Takeda Pharma Exercises Option for Licensing Agreement with Crescendo Biologics 217

Takeda Pharma Enters into Licensing Agreement with Enterome 218

ASKA Pharma Enters into Licensing Agreement with Takeda Pharma 219

FIMECS Enters into Licensing Agreement with Takeda Pharma 220

Rhythm Pharma Enters into Licensing Agreement with Takeda Pharma 221

Takeda Pharma to Enter into Licensing Agreement with Wave Life Sciences 222

Mesoblast Enters into Licensing Agreement with TiGenix 224

Izana Bioscience Enters into Licensing Agreement with Takeda Pharma 225

Hikma Pharma Enters into Licensing Agreement with Takeda Pharma for Dexilant 226

Hikma Pharma Expands Licensing Agreement with Takeda Pharma for Xefo 227

Hikma Pharma Enters into Licensing Agreement with Takeda Pharma for Vipedia and Edarbi 228

Takeda Pharma Enters into Licensing Agreement with Isogenica for llamdA 229

Millennium Pharma Enters into Licensing Agreement with Tesaro 230

Takeda Pharma Enters into Licensing Agreement with Selexis 231

Biological E Enters into Licensing Agreement with Takeda Pharma 232

Takeda Pharma Enters into Licensing Agreement with Finch Therapeutics 233

Katairo Enters into Licensing Agreement with Takeda Pharma 234

Takeda Pharma Enters into Licensing Agreement with Exelixis 235

Millennium Pharma Enters into Licensing Agreement with LegoChem Biosciences 236

Teva Pharma Enters into Licensing Agreement with Takeda for Attenukine 237

Takeda Pharma Enters into Licensing Agreement with TiGenix for Cx601 238

Teva Pharma Enters into Licensing Agreement with Takeda Pharma for Ninlaro 240

Takeda Pharma Enters into Licensing Agreement with Theravance Biopharma for TD-8954 241

Dermira Enters into Option Agreement with Takeda Pharma 242

Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for Relugolix 243

Incyte Amends Licensing Agreement with ARIAD Pharma 244

Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for RVT-602 245

Outpost Medicine Enters into Licensing Agreement with Takeda Pharma 246

Takeda Pharma Enters into Licensing Agreement with Gencia 247

Takeda Enters into Licensing Agreement with ImmunoGen 248

Takeda Enters into Licensing Agreement with Kaketsuken for Human Papillomavirus Vaccine 249

Mersana Exercises Option for License Agreement with Millennium 250

Sucampo Pharma Enters Into Licensing Agreement with Takeda Pharma 251

Takeda and Aska Pharma Enter into Licensing Agreement for Candesartan Aska 253

TiGenix Enters Licensing Agreement With Sobi for ChondroCelect 254

Sunesis Pharma Enters Into Licensing Agreement With Millennium Pharma 255

Takeda Pharma Enters Into Licensing Agreement With Arbor Pharma For Edarbi And Edarbyclor 256

NPS Pharma Enters Into Licensing Agreement With Takeda Pharma For Teduglutide And PTH 1-84 257

Apricus Biosciences Enters Into Licensing Agreement With Takeda Pharma For Vitaros 258

Takeda Pharma Enters into Licensing Agreement with Kaketsuken 259

Valeant Canada Enters into Licensing Agreement with Takeda Pharma for Edarbi and Edarbyclor 260

Takeda And Trianni Enter Into Licensing Agreement For Trianni Transgenic Mouse Platform 261

Takeda Pharma Enters Into Licensing Agreement With Natrogen Therapeutics For Inflammatory Bowel Disease 262

Teva Pharma Enters Into Licensing Agreement With Takeda Pharma For Glatiramer Acetate 263

Takeda California Enters Into Licensing Agreement With Sea Lane Biotech For ConCIRT Libraries and Technology 264

Daewoong Pharma Enters Into Licensing Agreement With Takeda Pharma For Instanyl 265

Takeda Expands Licensing Agreement With Genedata For Genedata Expressionist 266

Reborna Biosciences Raises USD2.3 Million in Private Placement of Shares 267

Infinity Pharma Plans to Raise USD2.5 Million in Public Offering of Shares 268

Arix Bioscience to Raise USD76.7 Million in Private Placement of Shares 269

Chordia Therapeutics Spin Out from Takeda Pharma 271

Molecular Templates Raises USD20 million in Equity Financing 272

TiGenix Raises USD35.7 Million in Public Offering of ADS 273

TiGenix to Raise USD10.4 Million in Private Placement of Shares 275

Ultragenyx Pharma Raises up to USD65 Million in Private Placement of Shares 276

TiGenix Raises USD26 Million in Private Placement of Shares 278

Aquinnah Pharma Raises USD5 Million in Private Placement of Shares 279

Prosetta Biosciences Raises USD31 Million in Series D Private Placement 280

TiGenix Raises USD9.2 Million in Private Placement of Shares 281

TiGenix Completes Private Placement Of Shares For USD 16.2 Million 282

TiGenix Completes Private Placement Of Shares For USD 8.5 Million 283

Ariad Pharma Completes Public Offering Of Common Stock For USD 323 Million 284

TiGenix Completes Private Placement Of Shares For USD 9 Million 286

Takeda Pharma to Raise up to USD20 Billion in Private Placement of Bonds 287

Takeda Pharma Raises USD500 Million in Private Placement of 2.45% Notes Due 2022 288

TiGenix Raises USD28.3 Million in Private Placement of 9% Bonds Due 2018 289

Ariad Pharma Raises USD200 Million in Private Placement of 3.625% Notes Due 2019 290

TiGenix Announces Private Placement Of Debt Securities For USD 13.7 Million 291

Takeda Pharma Completes Public Offering Of Fourteenth Series Bonds Due 2019 For USD 593.5 Million 292

Takeda Pharma Completes Public Offering Of Fifteenth Series Bonds Due 2020 For USD 593.5 Million 293

Takeda Pharma Completes Private Placement Of Notes Due 2015 For USD 1,500 Million 294

Takeda Pharma Completes Private Placement Of Notes Due 2017 For USD 1,500 Million 295

Takeda Pharma Completes Public Offering Of Eleventh Series Bonds Due 2016 For USD 870 Million 296

Takeda Pharma Completes Public Offering Of Twelfth Series Bonds Due 2017 For USD 745 Million 297

Takeda Pharma Completes Public Offering Of Thirteenth Series Bonds Due 2018 For USD 745 Million 298

Takeda Pharma May Sell Shire's Ophthalmology Products 299

Chinoin Pharma Acquires Colombian Production Unit from Takeda Pharma 300

Takeda Pharma Plans to Sell Additional Products to Teva Takeda Yakuhin for USD256.5 Million 301

Acino International Acquires Manufacturing Business from Takeda Pharma 302

AstraZeneca Acquires Core Respiratory Business from Takeda Pharmaceutical for USD575 Million 303

Fraunhofer ITEM Acquires Surfactant and CPA Program Assets from Takeda 304

PDL BioPharma Acquires Royalty Revenue of Iclusig from ARIAD Pharma for USD200 Million 305

Infinity Pharma Exercises Option to Acquire Duvelisib Royalty Rights from Takeda Pharma 307

Dr. Kade Pharma Acquires Portfolio Of OTC Products From Takeda 308

Caraco Pharma Completes Acquisition Of Non-Colcrys Business Of URL Pharma From Takeda Pharma For USD 65 Million 309

Takeda Pharma Acquires TiGenix for USD626.4 Million 310

Shanghai Pharma to Acquire 26.34% Stake in Techpool Bio-Pharma from Takeda Pharma for USD143.4 Million 312

Sunrise Bright to Acquire 25% Stake in Techpool Bio-Pharma from Takeda Pharma for USD135.8 Million 313

Takeda Pharma to Acquire Shire 314

Novamed Fabricacao de Produtos Farmaceuticos Acquires Multilab Industria e Comercio de Produtos Farmaceuticos from Takeda Pharma 317

Johnson & Johnson, Novartis and Takeda Pharma May Acquire Hypermarcas 318

Takeda Acquires Altos Therapeutics 320

Takeda Pharma Acquires Ariad Pharma for up to USD5.2 Billion in Tender Offer 321

Takeda Pharma May Acquire Salix Pharma for up to USD10 Billion 323

Incyte Acquires ARIAD Pharma (Luxembourg) for USD140 Million 324

TiGenix Acquires Coretherapix from Genetrix 326

Takeda to Acquire Neutec Total from Neutec for up to USD121 Million 327

Takeda Pharma Acquires Minority Stake in BioMotiv for USD25 Million 328

PharmaCell Completes Acquisition of TiGenix, Operator of Cell Therapy Production Facility in Netherlands for USD7.8 Million 329

AstraZeneca May Acquire Ariad Pharma 330

Takeda America Completes Acquisition Of Inviragen For USD 250 Million 332

Takeda Completes Acquisition Of Remaining 87.5% Stake In Envoy Therapeutics For Up To USD 140 Million 334

Takeda America Completes Acquisition Of LigoCyte Pharma For USD 60 Million 336

Takeda Pharma Invests USD 5 Million In Advinus Therapeutics 338

Takeda Completes Acquisition Of Multilab, Brazilian Drugmaker, For Up To USD 265 Million 339

Takeda America Completes Acquisition Of URL Pharma For USD 800 Million 341

Takeda Completes Acquisition Of Intellikine For USD 310 Million 343

Takeda Pharmaceutical Co Ltd, Key Competitors 345

Takeda Pharmaceutical Co Ltd, Key Employees 346

Takeda Pharmaceutical Co Ltd, Other Locations 347

Takeda Pharmaceutical Co Ltd, Subsidiaries 347

Takeda Pharmaceutical Co Ltd, Joint Venture 354

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Takeda Pharmaceutical Co Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Takeda Pharmaceutical Company Ltd (Takeda) is a research-based global pharmaceutical company which focuses on the research and development, manufacture, marketing, commercialization and import and export of pharmaceutical drugs and consumer health care products. The company manufactures and markets a wide range of products including photographic chemicals, inorganic chemicals, vitamin bulks, test reagents and clinical diagnostics. Takeda markets its drugs worldwide through its subsidiaries in North America, Europe and Asia. It operates production facilities in Osaka and Hikari in Japan; Italy; Ireland; Germany; Austria; Denmark; Belgium; Norway; Poland; Russia; China; Indonesia; Mexico; Brazil; Argentina; Columbia; Estonia; and India. It also operates research and development facilities at various locations in Japan and the US, China and the UK; and in Brazil, Germany, Switzerland, and Singapore. Takeda is headquartered in Chuo-ku, Osaka, Japan.

Takeda Pharmaceutical Co Ltd (4502)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 10

List of Figures 15

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 16

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 17

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 18

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 19

Takeda Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 21

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 22

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 44

Asset Purchase 44

Takeda Pharma Acquires Biologics Manufacturing Facility from Baxalta 44

Venture Financing 45

VelosBio Raises USD58 Million in Series A Financing 45

Ambys Medicines Raises USD60 Million in Series A Venture Financing 46

StrideBio Raises USD15.7 Million in Series A Financing 47

Cortexyme Raises USD76 Million in Series B Venture Financing 48

Crescendo Biologics Raises USD69.1 Million in Series B Venture Financing 50

Univercells Raises USD3.5 Million in Series A2 Financing 52

Hookipa Biotech Raises USD58.8 Million in Series C Financing 53

Obsidian Therapeutics Raises USD49.5 Million in Series A Financing 55

Chordia Therapeutics Raises Funds in Series A Financing 56

TiGenix Raises USD0.02 Million in Venture Financing 57

Outpost Medicine Raises Additional USD20 Million in Series A Financing 58

Palleon Pharma Raises USD47.6 Million in Series A Financing 59

OrphoMed Raises USD39 Million in Series A Financing 60

Biomx Raises USD24 Million in Series A Venture Financing 61

Avidity Biosciences Raises USD10 Million in Series B Venture Financing 63

Cerevance Raises USD21.5 Million in Series A Financing 65

Bioniz Therapeutics Raises USD13 Million in Series A Venture Financing 66

Mersana Therapeutics Raises USD33 Million in Series C Financing Round 67

Cortexyme Raises USD15 Million in Series A Financing Round 69

Protekt Therapeutics Raises More Than USD2 Million in Financing 70

Univercells Raises USD3.4 Million in Equity Financing Round 71

Encycle Therapeutics Raises USD2 Million in Seed Financing 72

Presage Biosciences Raises Funds through Venture Financing 73

Naurex Raises USD80 Million in Series C Venture Financing 74

Naurex Raises USD 25 Million In Venture Financing 76

VHsquared Secures Series A Funding Round 78

Hookipa Biotech Raises USD 27 Million In Series B Financing 79

TiGenix Raises USD8.5 Million in Venture Financing 81

Heptares Therapeutics Raises USD 21 Million In Series B Financing 82

Redwood Bioscience Raises USD 8.6 Million In Venture Financing 83

Naurex Raises USD 38 Million In Series B Financing 84

ArmaGen Technologies Raises USD 17 Million In Series A Financing 86

Juventas Therapeutics Raises USD 22.2 Million In Series B Venture Financing Round 88

LigoCyte Pharmaceuticals Raises USD 2 Million In Venture Financing Round 90

Private Equity 91

Valeant Pharma Rejects Joint Takeover Bid from Takeda Pharma and TPG Capital Management 91

Sarissa Capital Acquires 6.22% Stake In Ariad Pharma 92

Partnerships 93

Molecular Templates Enters into Agreement with Takeda Pharma 93

Ambys Medicines and Takeda Pharma Enter into Partnership Agreement 94

HiFiBiO Therapeutics Enters into Agreement with Takeda Pharma 95

leon-nanodrugs Enters into Agreement with Takeda Pharma 96

HaemaLogiX Enters into Research Collaboration Agreement Takeda Pharma 97

Nektar Therapeutics Enters into Clinical Collaboration with Takeda Pharma 98

Takeda Pharma Enters into Agreement with DNDi 99

Beacon Discovery Enters into Drug Discovery Agreement with Takeda Pharma 100

Fujifilm and Takeda Pharma Enter into Agreement 101

Takeda Pharma and Denali Therapeutics to Enter into Agreement 102

Takeda Pharma and Montreal Neurological Institute and Hospital Enter into Research Partnership 103

Takeda Pharma and Portal Instruments Enter into Agreement 104

Takeda Pharma and HemoShear Therapeutics Enter into Agreement 105

Recursion Pharma Enters into Agreement with Takeda Pharma 106

Takeda Pharma, Karolinska Institutet and Structural Genomics Consortium Enter into Agreement 107

HitGen Enters into Agreement with Takeda Pharma 108

Millennium Pharma and Noile-Immune Biotech Enter into Agreement 109

AstraZeneca and Takeda Pharma Enter into Co-Development Agreement 110

Samsung Bioepis Enters into Co-Development Agreement with Takeda Pharma 111

Millennium Pharma and Shattuck Labs Enter into Research Agreement 112

Takeda Pharma Partners with Stanford University 113

Takeda Pharma Enters into Research Agreement with Molecular Templates 114

Takeda Pharma and Cardurion Pharma Enter into Partnership 115

Takeda Pharma and Schrodinger Enter into Research Partnership 116

Prana Biotech Enters into Research Agreement with Takeda Pharma 117

Heidelberg Pharma Enters into Research Agreement with Takeda Pharma 118

Numerate Enters into Agreement with Takeda Pharma 119

Nektar Therapeutics Enters into Agreement with Takeda Pharma 120

Takeda Pharma and GammaDelta Therapeutics Enter into Partnership 121

Takeda Pharma and Harrington Discovery Institute Enter into Partnership 122

Takeda Pharma Enters into Agreement with NuBiyota 123

PRA Health Sciences and Takeda Pharma Form Joint Venture 124

Center for iPS Cell Research and Application, Takeda Pharma and RIKEN Enter into Partnership 125

INCJ, Takeda Pharma and MediPal Holdings Form Joint Venture 126

Innovation Network Corporation of Japan, Takeda Pharma and MEDIPAL HOLDINGS Enter into Partnership 127

Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 128

Takeda Pharma Enters into Agreement with Maverick Therapeutics 130

Takeda Pharma and Ovid Therapeutics Enter into Agreement 131

Takeda Pharma Enters into Development Agreement wtih PvP Biologics 133

Arcturus Therapeutics Extends Agreement with Takeda Pharma 134

CiRA, Takeda Pharma and Yokohama City University Enter into Research Agreement 135

EnGeneIC Enters into Agreement with Millennium Pharma 136

Takeda Pharma Enters into Agreement with Affilogic 137

Zydus Cadila Healthcare Enters into Agreement with Takeda Pharma 138

PRA Health Sciences Enters into Agreement with Takeda Pharma 139

Biomedical Advanced Research and Development Authority Enters into Agreement with Takeda Pharma 140

TB Alliance and Takeda Pharma Enter into Agreement 141

Ariad Pharma Enters into Distribution Agreement with Pint Pharma International 142

Ariad Pharma Enters into Distribution Agreement with Biologix 143

Takeda Pharma Enters into Agreement with M2Gen 144

Takeda Pharma Forms Joint Venture with Roivant Sciences 145

Takeda Pharma Enters into Co-Development Agreement with Ultragenyx Pharma 146

Astellas Pharma, Daiichi Sankyo and Takeda Pharma Enter into Research Agreement 147

Prosetta Biosciences Enters into Agreement with Takeda Pharma 148

Adimab Enters into Drug Discovery Agreement with Takeda Pharma 149

RaQualia Pharma Enters into Agreement with Takeda Pharma 150

TiGenix Forms Partnership with TFS International 151

Teva Pharma and Takeda Pharma Form Joint Venture 152

Takeda Pharma Enters into Research Agreement with University of Chicago and Icahn School of Medicine at Mount Sinai 154

Broad Institute Genomic Services Partners with Takeda Pharma 155

Takeda Pharma Enters into Partnership with enGene 156

Takeda Pharma Enters into Agreement with Enterome Bioscience 157

Vipergen Enters into Agreement with Takeda Pharma 158

Center for iPS Cell Research and Application Enters into Agreement with Takeda Pharma 159

Takeda Pharma Enters into R&D Agreement with Cour Pharma 160

University College London Enters into Research Agreement with Takeda Pharma 161

Takeda Pharma Enters into Agreement with Nanotherapeutics 162

DNDi Enters into Agreement with Takeda Pharma 163

ARIAD Pharma Enters into Distribution Agreement with Paladin 164

Takeda Pharma Enters into Agreement with Sanford-Burnham 165

National Cancer Center and Takeda Pharma to Develop Anti-Cancer Agents 166

Ariad Pharma Enters into Distribution Agreement with GEN Ilac 167

Takeda Enters into Research Agreement with Keio University School of Medicine and Niigata University 168

CiRA Enters into Co-Development Agreement with Takeda Pharma 169

BioXcel Enters into Agreement with Takeda Development Center Americas 170

Queen Mary University of London Enters into Research Agreement with Takeda Pharma 171

Prasco Lab Enters into Co-Marketing Agreement with Takeda Pharma 172

Ariad Pharma Enters into Co-Marketing Agreement with Angelini Pharma for Iclusig 173

Ariad Pharma Enters into Co-Marketing Agreement with Otsuka Pharma for Iclusig 174

Monash Institute and Monash University Enter into Research Agreement with Takeda Pharma 176

Presage Biosciences Expands its Research Agreement with Takeda Pharma 177

GE Healthcare Enters into R&D Agreement with Takeda Pharma 178

GVK Biosciences Forms Joint Venture with Takeda Pharma 179

MacroGenics Enters into Co-Development Agreement with Takeda Pharma 180

Meiji Seika Pharma Enters into Co-Promotion Agreement with Takeda Pharma for Rozerem 181

Takeda Pharma Enters Option Agreement with MacroGenics for MGD010 182

Pantec Biosolutions Enters into Research Agreement with Takeda Pharma 184

Teva Pharma Enters Into Agreement With Takeda Pharma To Commercialize Rasagiline In Japan 185

Mersana Therapeutics Expands Agreement with Takeda Pharma 186

Mersana Expands Co-Development Agreement with Takeda Pharma 187

Otsuka Enters Into Co-Promotion Agreement With Takeda For TAK-438 188

Takeda Enters into R&D Agreement with University College London 190

Ariad Pharma Enters Into Agreement With Specialised Therapeutics To Commercialize Iclusig In Australia 191

Takeda Pharma Enters Into Co-Marketing Agreement With Research Foundation For Microbial Diseases Of Osaka University 192

OrbiMed Israel Partners, JJDC and Takeda Ventures Form Joint Venture 193

Takeda Pharma Enters into Agreement with Medicines for Malaria Venture 194

TiGenix To Enter Into Co-Marketing Agreement For Cx601 195

Tri-Institutional Therapeutics Expands Agreement with Takeda Pharma 196

Takeda Nycomed Enters Into Co-Marketing Agreement With Shire For Calcichew D3 Portfolio 197

Takeda Pharma Enters Into Co-Promotion Agreement With Sanofi For Alogliptin 198

Interprotein Enters Into Agreement With Takeda Pharma For PPI Inhibitors 199

Scripps Research Institute Expands Research Agreement With Takeda 200

Takeda Pharma Enters Into Co-Development Agreement With Resolve Therapeutics 201

Sanford-Burnham And Florida Hospital Extend Research Agreement With Takeda 202

Gladstone Enters into Research Agreement with Takeda Pharma 204

Hyundai Pharma Enters into Distribution Agreement with Takeda Pharma for TachoSil 205

Takeda Pharma Enters Into Drug Discovery Agreement With Advinus Therapeutics 206

Takeda Pharma Enters Into Distribution Agreement With Johnson & Johnson For Seven OTC Brands 207

Jeil Pharma Enters Into Distribution Agreement With Takeda Pharma For Dexilant 208

Riken Enters Into Agreement With Takeda Pharma To Form Riken Bsi-Takeda Collaboration Center 209

Metabolon Enters Into Co-Development Agreement With Takeda Pharma 210

Seattle Genetics And Millennium Pharma Enter Into Co-Development Agreement With Ventana Medical Systems 211

Presage Biosciences Enters Into Co-Development Agreement With Millennium Pharma For Cancer Drugs 213

Affymax Enters Into Co-Promotion Agreement With Takeda For Peginesatide 214

CIC bioGUNE Enters into Agreement with Millennium Pharma 215

Takeda Pharma Enters Into Research Agreement With Osaka University 216

Licensing Agreements 217

Takeda Pharma Exercises Option for Licensing Agreement with Crescendo Biologics 217

Takeda Pharma Enters into Licensing Agreement with Enterome 218

ASKA Pharma Enters into Licensing Agreement with Takeda Pharma 219

FIMECS Enters into Licensing Agreement with Takeda Pharma 220

Rhythm Pharma Enters into Licensing Agreement with Takeda Pharma 221

Takeda Pharma to Enter into Licensing Agreement with Wave Life Sciences 222

Mesoblast Enters into Licensing Agreement with TiGenix 224

Izana Bioscience Enters into Licensing Agreement with Takeda Pharma 225

Hikma Pharma Enters into Licensing Agreement with Takeda Pharma for Dexilant 226

Hikma Pharma Expands Licensing Agreement with Takeda Pharma for Xefo 227

Hikma Pharma Enters into Licensing Agreement with Takeda Pharma for Vipedia and Edarbi 228

Takeda Pharma Enters into Licensing Agreement with Isogenica for llamdA 229

Millennium Pharma Enters into Licensing Agreement with Tesaro 230

Takeda Pharma Enters into Licensing Agreement with Selexis 231

Biological E Enters into Licensing Agreement with Takeda Pharma 232

Takeda Pharma Enters into Licensing Agreement with Finch Therapeutics 233

Katairo Enters into Licensing Agreement with Takeda Pharma 234

Takeda Pharma Enters into Licensing Agreement with Exelixis 235

Millennium Pharma Enters into Licensing Agreement with LegoChem Biosciences 236

Teva Pharma Enters into Licensing Agreement with Takeda for Attenukine 237

Takeda Pharma Enters into Licensing Agreement with TiGenix for Cx601 238

Teva Pharma Enters into Licensing Agreement with Takeda Pharma for Ninlaro 240

Takeda Pharma Enters into Licensing Agreement with Theravance Biopharma for TD-8954 241

Dermira Enters into Option Agreement with Takeda Pharma 242

Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for Relugolix 243

Incyte Amends Licensing Agreement with ARIAD Pharma 244

Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for RVT-602 245

Outpost Medicine Enters into Licensing Agreement with Takeda Pharma 246

Takeda Pharma Enters into Licensing Agreement with Gencia 247

Takeda Enters into Licensing Agreement with ImmunoGen 248

Takeda Enters into Licensing Agreement with Kaketsuken for Human Papillomavirus Vaccine 249

Mersana Exercises Option for License Agreement with Millennium 250

Sucampo Pharma Enters Into Licensing Agreement with Takeda Pharma 251

Takeda and Aska Pharma Enter into Licensing Agreement for Candesartan Aska 253

TiGenix Enters Licensing Agreement With Sobi for ChondroCelect 254

Sunesis Pharma Enters Into Licensing Agreement With Millennium Pharma 255

Takeda Pharma Enters Into Licensing Agreement With Arbor Pharma For Edarbi And Edarbyclor 256

NPS Pharma Enters Into Licensing Agreement With Takeda Pharma For Teduglutide And PTH 1-84 257

Apricus Biosciences Enters Into Licensing Agreement With Takeda Pharma For Vitaros 258

Takeda Pharma Enters into Licensing Agreement with Kaketsuken 259

Valeant Canada Enters into Licensing Agreement with Takeda Pharma for Edarbi and Edarbyclor 260

Takeda And Trianni Enter Into Licensing Agreement For Trianni Transgenic Mouse Platform 261

Takeda Pharma Enters Into Licensing Agreement With Natrogen Therapeutics For Inflammatory Bowel Disease 262

Teva Pharma Enters Into Licensing Agreement With Takeda Pharma For Glatiramer Acetate 263

Takeda California Enters Into Licensing Agreement With Sea Lane Biotech For ConCIRT Libraries and Technology 264

Daewoong Pharma Enters Into Licensing Agreement With Takeda Pharma For Instanyl 265

Takeda Expands Licensing Agreement With Genedata For Genedata Expressionist 266

Equity Offering 267

Reborna Biosciences Raises USD2.3 Million in Private Placement of Shares 267

Infinity Pharma Plans to Raise USD2.5 Million in Public Offering of Shares 268

Arix Bioscience to Raise USD76.7 Million in Private Placement of Shares 269

Chordia Therapeutics Spin Out from Takeda Pharma 271

Molecular Templates Raises USD20 million in Equity Financing 272

TiGenix Raises USD35.7 Million in Public Offering of ADS 273

TiGenix to Raise USD10.4 Million in Private Placement of Shares 275

Ultragenyx Pharma Raises up to USD65 Million in Private Placement of Shares 276

TiGenix Raises USD26 Million in Private Placement of Shares 278

Aquinnah Pharma Raises USD5 Million in Private Placement of Shares 279

Prosetta Biosciences Raises USD31 Million in Series D Private Placement 280

TiGenix Raises USD9.2 Million in Private Placement of Shares 281

TiGenix Completes Private Placement Of Shares For USD 16.2 Million 282

TiGenix Completes Private Placement Of Shares For USD 8.5 Million 283

Ariad Pharma Completes Public Offering Of Common Stock For USD 323 Million 284

TiGenix Completes Private Placement Of Shares For USD 9 Million 286

Debt Offering 287

Takeda Pharma to Raise up to USD20 Billion in Private Placement of Bonds 287

Takeda Pharma Raises USD500 Million in Private Placement of 2.45% Notes Due 2022 288

TiGenix Raises USD28.3 Million in Private Placement of 9% Bonds Due 2018 289

Ariad Pharma Raises USD200 Million in Private Placement of 3.625% Notes Due 2019 290

TiGenix Announces Private Placement Of Debt Securities For USD 13.7 Million 291

Takeda Pharma Completes Public Offering Of Fourteenth Series Bonds Due 2019 For USD 593.5 Million 292

Takeda Pharma Completes Public Offering Of Fifteenth Series Bonds Due 2020 For USD 593.5 Million 293

Takeda Pharma Completes Private Placement Of Notes Due 2015 For USD 1,500 Million 294

Takeda Pharma Completes Private Placement Of Notes Due 2017 For USD 1,500 Million 295

Takeda Pharma Completes Public Offering Of Eleventh Series Bonds Due 2016 For USD 870 Million 296

Takeda Pharma Completes Public Offering Of Twelfth Series Bonds Due 2017 For USD 745 Million 297

Takeda Pharma Completes Public Offering Of Thirteenth Series Bonds Due 2018 For USD 745 Million 298

Asset Transactions 299

Takeda Pharma May Sell Shire's Ophthalmology Products 299

Chinoin Pharma Acquires Colombian Production Unit from Takeda Pharma 300

Takeda Pharma Plans to Sell Additional Products to Teva Takeda Yakuhin for USD256.5 Million 301

Acino International Acquires Manufacturing Business from Takeda Pharma 302

AstraZeneca Acquires Core Respiratory Business from Takeda Pharmaceutical for USD575 Million 303

Fraunhofer ITEM Acquires Surfactant and CPA Program Assets from Takeda 304

PDL BioPharma Acquires Royalty Revenue of Iclusig from ARIAD Pharma for USD200 Million 305

Infinity Pharma Exercises Option to Acquire Duvelisib Royalty Rights from Takeda Pharma 307

Dr. Kade Pharma Acquires Portfolio Of OTC Products From Takeda 308

Caraco Pharma Completes Acquisition Of Non-Colcrys Business Of URL Pharma From Takeda Pharma For USD 65 Million 309

Acquisition 310

Takeda Pharma Acquires TiGenix for USD626.4 Million 310

Shanghai Pharma to Acquire 26.34% Stake in Techpool Bio-Pharma from Takeda Pharma for USD143.4 Million 312

Sunrise Bright to Acquire 25% Stake in Techpool Bio-Pharma from Takeda Pharma for USD135.8 Million 313

Takeda Pharma to Acquire Shire 314

Novamed Fabricacao de Produtos Farmaceuticos Acquires Multilab Industria e Comercio de Produtos Farmaceuticos from Takeda Pharma 317

Johnson & Johnson, Novartis and Takeda Pharma May Acquire Hypermarcas 318

Takeda Acquires Altos Therapeutics 320

Takeda Pharma Acquires Ariad Pharma for up to USD5.2 Billion in Tender Offer 321

Takeda Pharma May Acquire Salix Pharma for up to USD10 Billion 323

Incyte Acquires ARIAD Pharma (Luxembourg) for USD140 Million 324

TiGenix Acquires Coretherapix from Genetrix 326

Takeda to Acquire Neutec Total from Neutec for up to USD121 Million 327

Takeda Pharma Acquires Minority Stake in BioMotiv for USD25 Million 328

PharmaCell Completes Acquisition of TiGenix, Operator of Cell Therapy Production Facility in Netherlands for USD7.8 Million 329

AstraZeneca May Acquire Ariad Pharma 330

Takeda America Completes Acquisition Of Inviragen For USD 250 Million 332

Takeda Completes Acquisition Of Remaining 87.5% Stake In Envoy Therapeutics For Up To USD 140 Million 334

Takeda America Completes Acquisition Of LigoCyte Pharma For USD 60 Million 336

Takeda Pharma Invests USD 5 Million In Advinus Therapeutics 338

Takeda Completes Acquisition Of Multilab, Brazilian Drugmaker, For Up To USD 265 Million 339

Takeda America Completes Acquisition Of URL Pharma For USD 800 Million 341

Takeda Completes Acquisition Of Intellikine For USD 310 Million 343

Takeda Pharmaceutical Co Ltd - Key Competitors 345

Takeda Pharmaceutical Co Ltd - Key Employees 346

Takeda Pharmaceutical Co Ltd - Locations And Subsidiaries 347

Head Office 347

Other Locations & Subsidiaries 347

Joint Venture 354

Recent Developments 356

Strategy And Business Planning 356

Sep 21, 2018: Takeda and Molecular Templates partner on protein-based cancer therapy 356

Aug 10, 2018: Ambys Medicines and Takeda to develop new therapies for liver diseases 357

Oct 01, 2017: ChromaJean to Launch at Takeda's Shonan Research Center 358

Jul 31, 2017: SEEDSUPPLY to Launch at Takedas Shonan Research Center 359

Jul 10, 2017: Takeda Announces the Start of Operations for AXCELEAD at its Shonan Research Center 360

Jun 16, 2017: Takeda Announces Completion of New Manufacturing Facilities at the Oranienburg Site in Germany 361

May 15, 2017: Takeda Announces Establishment of its Wholly-owned Subsidiary at Shonan Research Center which Supports Drug Discovery to Drive Innovation 362

Apr 03, 2017: Takeda Consumer Healthcare Company starts its business 363

Feb 20, 2017: Takeda Announces Further Details of Splitting off (Simple Absorption-type Split) of Japan Consumer Healthcare Business Unit 364

Financial Announcements 366

Oct 31, 2018: Takeda reports second quarter FY2018 results 366

Jul 31, 2018: Takeda reports first quarter financial result 2018 results 368

May 14, 2018: Takeda reports FY2017 full year results and issues FY2018 guidance 370

Feb 01, 2018: Takeda Reports 3rd Quarter FY2017 Results 372

Nov 01, 2017: Takeda Reports First Half FY2017 Results 373

Jul 27, 2017: Takeda reports 1st Quarter FY2017 results 374

May 10, 2017: Takeda reports FY2016 full year results and issues FY2017 guidance 375

Feb 01, 2017: Takeda reports Q3 FY2016 results and improves year-end outlook 376

Corporate Communications 377

Mar 08, 2018: Takeda Announces Resignation of James Kehoe and Appointment of Costa Saroukos as CFO 377

Mar 30, 2017: Takeda Announces Ricardo Marek as New President of Emerging Markets Business Unit 378

Government and Public Interest 379

Jul 09, 2018: Takeda Announces Selection of Three New Programs for Global Corporate Social Responsibility CSR Program 2018 Promoting Disease Prevention to Improve Health in Developing and Emerging Countries 379

Jun 07, 2018: Takeda pioneers NICEs new service for economic model review 381

Jul 27, 2017: Takeda selected by major index and sustainability rating institutions concerning Corporate Social Responsibility 382

Jun 30, 2017: Takeda Announces Selection of Global CSR Programs Emphasizing Prevention for Health in Developing and Emerging Countries 383

Feb 08, 2017: Takeda Presents $1 Million Gift to the Koch Institute for Integrative Cancer Research at MIT to Support Immuno-oncology Research 384

Product News 385

06/22/2017: NICE approves COPD treatment roflumilast for routine NHS use 385

Product Approvals 386

Sep 11, 2017: AstraZenecas Daxas Rejects For Use Within NHS Scotland 386

Apr 28, 2017: NICE issues ponatinib recommendation 387

Clinical Trials 388

Aug 13, 2018: Samsung Bioepis to begin Phase l trial of SB26 for pancreatitis 388

Mar 22, 2018: Takeda Announces Publication of Final Data from ICLUSIG (ponatinib) Pivotal Phase 2 PACE Trial in Blood 389

Nov 01, 2017: Data To Be Presented On ICLUSIG (ponatinib) During 59th American Society of Hematology Annual Meeting 391

Nov 01, 2017: Incyte Presents Ponatinib Data at 59th Annual ASH Meeting 392

Other Significant Developments 393

Aug 15, 2018: Crescendo Biologics reaches technical milestone for a second target in strategic collaboration with Takeda 393

Jul 02, 2018: Takeda Global Headquarters Grand Opening 394

Mar 20, 2018: Completion of Takeda Global Headquarters 395

Nov 10, 2017: Takeda Supports Launch of Five-Year, $1M Initiative Spearheaded by the Massachusetts Life Sciences Center to Back Women-Driven Early Stage Companies 396

Mar 13, 2017: INCJ, Takeda, and MEDIPAL HOLDINGS Partner to Launch a Biotech Venture 397

Appendix 398

Methodology 398

About GlobalData 398

Contact Us 398

Disclaimer 398


List Of Figure

List of Figures

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 16

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 17

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 18

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 19

Takeda Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 21


List Of Table

List of Tables

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 16

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 17

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 18

Takeda Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 19

Takeda Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 21

Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 22

Takeda Pharma Acquires Biologics Manufacturing Facility from Baxalta 44

VelosBio Raises USD58 Million in Series A Financing 45

Ambys Medicines Raises USD60 Million in Series A Venture Financing 46

StrideBio Raises USD15.7 Million in Series A Financing 47

Cortexyme Raises USD76 Million in Series B Venture Financing 48

Crescendo Biologics Raises USD69.1 Million in Series B Venture Financing 50

Univercells Raises USD3.5 Million in Series A2 Financing 52

Hookipa Biotech Raises USD58.8 Million in Series C Financing 53

Obsidian Therapeutics Raises USD49.5 Million in Series A Financing 55

Chordia Therapeutics Raises Funds in Series A Financing 56

TiGenix Raises USD0.02 Million in Venture Financing 57

Outpost Medicine Raises Additional USD20 Million in Series A Financing 58

Palleon Pharma Raises USD47.6 Million in Series A Financing 59

OrphoMed Raises USD39 Million in Series A Financing 60

Biomx Raises USD24 Million in Series A Venture Financing 61

Avidity Biosciences Raises USD10 Million in Series B Venture Financing 63

Cerevance Raises USD21.5 Million in Series A Financing 65

Bioniz Therapeutics Raises USD13 Million in Series A Venture Financing 66

Mersana Therapeutics Raises USD33 Million in Series C Financing Round 67

Cortexyme Raises USD15 Million in Series A Financing Round 69

Protekt Therapeutics Raises More Than USD2 Million in Financing 70

Univercells Raises USD3.4 Million in Equity Financing Round 71

Encycle Therapeutics Raises USD2 Million in Seed Financing 72

Presage Biosciences Raises Funds through Venture Financing 73

Naurex Raises USD80 Million in Series C Venture Financing 74

Naurex Raises USD 25 Million In Venture Financing 76

VHsquared Secures Series A Funding Round 78

Hookipa Biotech Raises USD 27 Million In Series B Financing 79

TiGenix Raises USD8.5 Million in Venture Financing 81

Heptares Therapeutics Raises USD 21 Million In Series B Financing 82

Redwood Bioscience Raises USD 8.6 Million In Venture Financing 83

Naurex Raises USD 38 Million In Series B Financing 84

ArmaGen Technologies Raises USD 17 Million In Series A Financing 86

Juventas Therapeutics Raises USD 22.2 Million In Series B Venture Financing Round 88

LigoCyte Pharmaceuticals Raises USD 2 Million In Venture Financing Round 90

Valeant Pharma Rejects Joint Takeover Bid from Takeda Pharma and TPG Capital Management 91

Sarissa Capital Acquires 6.22% Stake In Ariad Pharma 92

Molecular Templates Enters into Agreement with Takeda Pharma 93

Ambys Medicines and Takeda Pharma Enter into Partnership Agreement 94

HiFiBiO Therapeutics Enters into Agreement with Takeda Pharma 95

leon-nanodrugs Enters into Agreement with Takeda Pharma 96

HaemaLogiX Enters into Research Collaboration Agreement Takeda Pharma 97

Nektar Therapeutics Enters into Clinical Collaboration with Takeda Pharma 98

Takeda Pharma Enters into Agreement with DNDi 99

Beacon Discovery Enters into Drug Discovery Agreement with Takeda Pharma 100

Fujifilm and Takeda Pharma Enter into Agreement 101

Takeda Pharma and Denali Therapeutics to Enter into Agreement 102

Takeda Pharma and Montreal Neurological Institute and Hospital Enter into Research Partnership 103

Takeda Pharma and Portal Instruments Enter into Agreement 104

Takeda Pharma and HemoShear Therapeutics Enter into Agreement 105

Recursion Pharma Enters into Agreement with Takeda Pharma 106

Takeda Pharma, Karolinska Institutet and Structural Genomics Consortium Enter into Agreement 107

HitGen Enters into Agreement with Takeda Pharma 108

Millennium Pharma and Noile-Immune Biotech Enter into Agreement 109

AstraZeneca and Takeda Pharma Enter into Co-Development Agreement 110

Samsung Bioepis Enters into Co-Development Agreement with Takeda Pharma 111

Millennium Pharma and Shattuck Labs Enter into Research Agreement 112

Takeda Pharma Partners with Stanford University 113

Takeda Pharma Enters into Research Agreement with Molecular Templates 114

Takeda Pharma and Cardurion Pharma Enter into Partnership 115

Takeda Pharma and Schrodinger Enter into Research Partnership 116

Prana Biotech Enters into Research Agreement with Takeda Pharma 117

Heidelberg Pharma Enters into Research Agreement with Takeda Pharma 118

Numerate Enters into Agreement with Takeda Pharma 119

Nektar Therapeutics Enters into Agreement with Takeda Pharma 120

Takeda Pharma and GammaDelta Therapeutics Enter into Partnership 121

Takeda Pharma and Harrington Discovery Institute Enter into Partnership 122

Takeda Pharma Enters into Agreement with NuBiyota 123

PRA Health Sciences and Takeda Pharma Form Joint Venture 124

Center for iPS Cell Research and Application, Takeda Pharma and RIKEN Enter into Partnership 125

INCJ, Takeda Pharma and MediPal Holdings Form Joint Venture 126

Innovation Network Corporation of Japan, Takeda Pharma and MEDIPAL HOLDINGS Enter into Partnership 127

Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 128

Takeda Pharma Enters into Agreement with Maverick Therapeutics 130

Takeda Pharma and Ovid Therapeutics Enter into Agreement 131

Takeda Pharma Enters into Development Agreement wtih PvP Biologics 133

Arcturus Therapeutics Extends Agreement with Takeda Pharma 134

CiRA, Takeda Pharma and Yokohama City University Enter into Research Agreement 135

EnGeneIC Enters into Agreement with Millennium Pharma 136

Takeda Pharma Enters into Agreement with Affilogic 137

Zydus Cadila Healthcare Enters into Agreement with Takeda Pharma 138

PRA Health Sciences Enters into Agreement with Takeda Pharma 139

Biomedical Advanced Research and Development Authority Enters into Agreement with Takeda Pharma 140

TB Alliance and Takeda Pharma Enter into Agreement 141

Ariad Pharma Enters into Distribution Agreement with Pint Pharma International 142

Ariad Pharma Enters into Distribution Agreement with Biologix 143

Takeda Pharma Enters into Agreement with M2Gen 144

Takeda Pharma Forms Joint Venture with Roivant Sciences 145

Takeda Pharma Enters into Co-Development Agreement with Ultragenyx Pharma 146

Astellas Pharma, Daiichi Sankyo and Takeda Pharma Enter into Research Agreement 147

Prosetta Biosciences Enters into Agreement with Takeda Pharma 148

Adimab Enters into Drug Discovery Agreement with Takeda Pharma 149

RaQualia Pharma Enters into Agreement with Takeda Pharma 150

TiGenix Forms Partnership with TFS International 151

Teva Pharma and Takeda Pharma Form Joint Venture 152

Takeda Pharma Enters into Research Agreement with University of Chicago and Icahn School of Medicine at Mount Sinai 154

Broad Institute Genomic Services Partners with Takeda Pharma 155

Takeda Pharma Enters into Partnership with enGene 156

Takeda Pharma Enters into Agreement with Enterome Bioscience 157

Vipergen Enters into Agreement with Takeda Pharma 158

Center for iPS Cell Research and Application Enters into Agreement with Takeda Pharma 159

Takeda Pharma Enters into R&D Agreement with Cour Pharma 160

University College London Enters into Research Agreement with Takeda Pharma 161

Takeda Pharma Enters into Agreement with Nanotherapeutics 162

DNDi Enters into Agreement with Takeda Pharma 163

ARIAD Pharma Enters into Distribution Agreement with Paladin 164

Takeda Pharma Enters into Agreement with Sanford-Burnham 165

National Cancer Center and Takeda Pharma to Develop Anti-Cancer Agents 166

Ariad Pharma Enters into Distribution Agreement with GEN Ilac 167

Takeda Enters into Research Agreement with Keio University School of Medicine and Niigata University 168

CiRA Enters into Co-Development Agreement with Takeda Pharma 169

BioXcel Enters into Agreement with Takeda Development Center Americas 170

Queen Mary University of London Enters into Research Agreement with Takeda Pharma 171

Prasco Lab Enters into Co-Marketing Agreement with Takeda Pharma 172

Ariad Pharma Enters into Co-Marketing Agreement with Angelini Pharma for Iclusig 173

Ariad Pharma Enters into Co-Marketing Agreement with Otsuka Pharma for Iclusig 174

Monash Institute and Monash University Enter into Research Agreement with Takeda Pharma 176

Presage Biosciences Expands its Research Agreement with Takeda Pharma 177

GE Healthcare Enters into R&D Agreement with Takeda Pharma 178

GVK Biosciences Forms Joint Venture with Takeda Pharma 179

MacroGenics Enters into Co-Development Agreement with Takeda Pharma 180

Meiji Seika Pharma Enters into Co-Promotion Agreement with Takeda Pharma for Rozerem 181

Takeda Pharma Enters Option Agreement with MacroGenics for MGD010 182

Pantec Biosolutions Enters into Research Agreement with Takeda Pharma 184

Teva Pharma Enters Into Agreement With Takeda Pharma To Commercialize Rasagiline In Japan 185

Mersana Therapeutics Expands Agreement with Takeda Pharma 186

Mersana Expands Co-Development Agreement with Takeda Pharma 187

Otsuka Enters Into Co-Promotion Agreement With Takeda For TAK-438 188

Takeda Enters into R&D Agreement with University College London 190

Ariad Pharma Enters Into Agreement With Specialised Therapeutics To Commercialize Iclusig In Australia 191

Takeda Pharma Enters Into Co-Marketing Agreement With Research Foundation For Microbial Diseases Of Osaka University 192

OrbiMed Israel Partners, JJDC and Takeda Ventures Form Joint Venture 193

Takeda Pharma Enters into Agreement with Medicines for Malaria Venture 194

TiGenix To Enter Into Co-Marketing Agreement For Cx601 195

Tri-Institutional Therapeutics Expands Agreement with Takeda Pharma 196

Takeda Nycomed Enters Into Co-Marketing Agreement With Shire For Calcichew D3 Portfolio 197

Takeda Pharma Enters Into Co-Promotion Agreement With Sanofi For Alogliptin 198

Interprotein Enters Into Agreement With Takeda Pharma For PPI Inhibitors 199

Scripps Research Institute Expands Research Agreement With Takeda 200

Takeda Pharma Enters Into Co-Development Agreement With Resolve Therapeutics 201

Sanford-Burnham And Florida Hospital Extend Research Agreement With Takeda 202

Gladstone Enters into Research Agreement with Takeda Pharma 204

Hyundai Pharma Enters into Distribution Agreement with Takeda Pharma for TachoSil 205

Takeda Pharma Enters Into Drug Discovery Agreement With Advinus Therapeutics 206

Takeda Pharma Enters Into Distribution Agreement With Johnson & Johnson For Seven OTC Brands 207

Jeil Pharma Enters Into Distribution Agreement With Takeda Pharma For Dexilant 208

Riken Enters Into Agreement With Takeda Pharma To Form Riken Bsi-Takeda Collaboration Center 209

Metabolon Enters Into Co-Development Agreement With Takeda Pharma 210

Seattle Genetics And Millennium Pharma Enter Into Co-Development Agreement With Ventana Medical Systems 211

Presage Biosciences Enters Into Co-Development Agreement With Millennium Pharma For Cancer Drugs 213

Affymax Enters Into Co-Promotion Agreement With Takeda For Peginesatide 214

CIC bioGUNE Enters into Agreement with Millennium Pharma 215

Takeda Pharma Enters Into Research Agreement With Osaka University 216

Takeda Pharma Exercises Option for Licensing Agreement with Crescendo Biologics 217

Takeda Pharma Enters into Licensing Agreement with Enterome 218

ASKA Pharma Enters into Licensing Agreement with Takeda Pharma 219

FIMECS Enters into Licensing Agreement with Takeda Pharma 220

Rhythm Pharma Enters into Licensing Agreement with Takeda Pharma 221

Takeda Pharma to Enter into Licensing Agreement with Wave Life Sciences 222

Mesoblast Enters into Licensing Agreement with TiGenix 224

Izana Bioscience Enters into Licensing Agreement with Takeda Pharma 225

Hikma Pharma Enters into Licensing Agreement with Takeda Pharma for Dexilant 226

Hikma Pharma Expands Licensing Agreement with Takeda Pharma for Xefo 227

Hikma Pharma Enters into Licensing Agreement with Takeda Pharma for Vipedia and Edarbi 228

Takeda Pharma Enters into Licensing Agreement with Isogenica for llamdA 229

Millennium Pharma Enters into Licensing Agreement with Tesaro 230

Takeda Pharma Enters into Licensing Agreement with Selexis 231

Biological E Enters into Licensing Agreement with Takeda Pharma 232

Takeda Pharma Enters into Licensing Agreement with Finch Therapeutics 233

Katairo Enters into Licensing Agreement with Takeda Pharma 234

Takeda Pharma Enters into Licensing Agreement with Exelixis 235

Millennium Pharma Enters into Licensing Agreement with LegoChem Biosciences 236

Teva Pharma Enters into Licensing Agreement with Takeda for Attenukine 237

Takeda Pharma Enters into Licensing Agreement with TiGenix for Cx601 238

Teva Pharma Enters into Licensing Agreement with Takeda Pharma for Ninlaro 240

Takeda Pharma Enters into Licensing Agreement with Theravance Biopharma for TD-8954 241

Dermira Enters into Option Agreement with Takeda Pharma 242

Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for Relugolix 243

Incyte Amends Licensing Agreement with ARIAD Pharma 244

Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for RVT-602 245

Outpost Medicine Enters into Licensing Agreement with Takeda Pharma 246

Takeda Pharma Enters into Licensing Agreement with Gencia 247

Takeda Enters into Licensing Agreement with ImmunoGen 248

Takeda Enters into Licensing Agreement with Kaketsuken for Human Papillomavirus Vaccine 249

Mersana Exercises Option for License Agreement with Millennium 250

Sucampo Pharma Enters Into Licensing Agreement with Takeda Pharma 251

Takeda and Aska Pharma Enter into Licensing Agreement for Candesartan Aska 253

TiGenix Enters Licensing Agreement With Sobi for ChondroCelect 254

Sunesis Pharma Enters Into Licensing Agreement With Millennium Pharma 255

Takeda Pharma Enters Into Licensing Agreement With Arbor Pharma For Edarbi And Edarbyclor 256

NPS Pharma Enters Into Licensing Agreement With Takeda Pharma For Teduglutide And PTH 1-84 257

Apricus Biosciences Enters Into Licensing Agreement With Takeda Pharma For Vitaros 258

Takeda Pharma Enters into Licensing Agreement with Kaketsuken 259

Valeant Canada Enters into Licensing Agreement with Takeda Pharma for Edarbi and Edarbyclor 260

Takeda And Trianni Enter Into Licensing Agreement For Trianni Transgenic Mouse Platform 261

Takeda Pharma Enters Into Licensing Agreement With Natrogen Therapeutics For Inflammatory Bowel Disease 262

Teva Pharma Enters Into Licensing Agreement With Takeda Pharma For Glatiramer Acetate 263

Takeda California Enters Into Licensing Agreement With Sea Lane Biotech For ConCIRT Libraries and Technology 264

Daewoong Pharma Enters Into Licensing Agreement With Takeda Pharma For Instanyl 265

Takeda Expands Licensing Agreement With Genedata For Genedata Expressionist 266

Reborna Biosciences Raises USD2.3 Million in Private Placement of Shares 267

Infinity Pharma Plans to Raise USD2.5 Million in Public Offering of Shares 268

Arix Bioscience to Raise USD76.7 Million in Private Placement of Shares 269

Chordia Therapeutics Spin Out from Takeda Pharma 271

Molecular Templates Raises USD20 million in Equity Financing 272

TiGenix Raises USD35.7 Million in Public Offering of ADS 273

TiGenix to Raise USD10.4 Million in Private Placement of Shares 275

Ultragenyx Pharma Raises up to USD65 Million in Private Placement of Shares 276

TiGenix Raises USD26 Million in Private Placement of Shares 278

Aquinnah Pharma Raises USD5 Million in Private Placement of Shares 279

Prosetta Biosciences Raises USD31 Million in Series D Private Placement 280

TiGenix Raises USD9.2 Million in Private Placement of Shares 281

TiGenix Completes Private Placement Of Shares For USD 16.2 Million 282

TiGenix Completes Private Placement Of Shares For USD 8.5 Million 283

Ariad Pharma Completes Public Offering Of Common Stock For USD 323 Million 284

TiGenix Completes Private Placement Of Shares For USD 9 Million 286

Takeda Pharma to Raise up to USD20 Billion in Private Placement of Bonds 287

Takeda Pharma Raises USD500 Million in Private Placement of 2.45% Notes Due 2022 288

TiGenix Raises USD28.3 Million in Private Placement of 9% Bonds Due 2018 289

Ariad Pharma Raises USD200 Million in Private Placement of 3.625% Notes Due 2019 290

TiGenix Announces Private Placement Of Debt Securities For USD 13.7 Million 291

Takeda Pharma Completes Public Offering Of Fourteenth Series Bonds Due 2019 For USD 593.5 Million 292

Takeda Pharma Completes Public Offering Of Fifteenth Series Bonds Due 2020 For USD 593.5 Million 293

Takeda Pharma Completes Private Placement Of Notes Due 2015 For USD 1,500 Million 294

Takeda Pharma Completes Private Placement Of Notes Due 2017 For USD 1,500 Million 295

Takeda Pharma Completes Public Offering Of Eleventh Series Bonds Due 2016 For USD 870 Million 296

Takeda Pharma Completes Public Offering Of Twelfth Series Bonds Due 2017 For USD 745 Million 297

Takeda Pharma Completes Public Offering Of Thirteenth Series Bonds Due 2018 For USD 745 Million 298

Takeda Pharma May Sell Shire's Ophthalmology Products 299

Chinoin Pharma Acquires Colombian Production Unit from Takeda Pharma 300

Takeda Pharma Plans to Sell Additional Products to Teva Takeda Yakuhin for USD256.5 Million 301

Acino International Acquires Manufacturing Business from Takeda Pharma 302

AstraZeneca Acquires Core Respiratory Business from Takeda Pharmaceutical for USD575 Million 303

Fraunhofer ITEM Acquires Surfactant and CPA Program Assets from Takeda 304

PDL BioPharma Acquires Royalty Revenue of Iclusig from ARIAD Pharma for USD200 Million 305

Infinity Pharma Exercises Option to Acquire Duvelisib Royalty Rights from Takeda Pharma 307

Dr. Kade Pharma Acquires Portfolio Of OTC Products From Takeda 308

Caraco Pharma Completes Acquisition Of Non-Colcrys Business Of URL Pharma From Takeda Pharma For USD 65 Million 309

Takeda Pharma Acquires TiGenix for USD626.4 Million 310

Shanghai Pharma to Acquire 26.34% Stake in Techpool Bio-Pharma from Takeda Pharma for USD143.4 Million 312

Sunrise Bright to Acquire 25% Stake in Techpool Bio-Pharma from Takeda Pharma for USD135.8 Million 313

Takeda Pharma to Acquire Shire 314

Novamed Fabricacao de Produtos Farmaceuticos Acquires Multilab Industria e Comercio de Produtos Farmaceuticos from Takeda Pharma 317

Johnson & Johnson, Novartis and Takeda Pharma May Acquire Hypermarcas 318

Takeda Acquires Altos Therapeutics 320

Takeda Pharma Acquires Ariad Pharma for up to USD5.2 Billion in Tender Offer 321

Takeda Pharma May Acquire Salix Pharma for up to USD10 Billion 323

Incyte Acquires ARIAD Pharma (Luxembourg) for USD140 Million 324

TiGenix Acquires Coretherapix from Genetrix 326

Takeda to Acquire Neutec Total from Neutec for up to USD121 Million 327

Takeda Pharma Acquires Minority Stake in BioMotiv for USD25 Million 328

PharmaCell Completes Acquisition of TiGenix, Operator of Cell Therapy Production Facility in Netherlands for USD7.8 Million 329

AstraZeneca May Acquire Ariad Pharma 330

Takeda America Completes Acquisition Of Inviragen For USD 250 Million 332

Takeda Completes Acquisition Of Remaining 87.5% Stake In Envoy Therapeutics For Up To USD 140 Million 334

Takeda America Completes Acquisition Of LigoCyte Pharma For USD 60 Million 336

Takeda Pharma Invests USD 5 Million In Advinus Therapeutics 338

Takeda Completes Acquisition Of Multilab, Brazilian Drugmaker, For Up To USD 265 Million 339

Takeda America Completes Acquisition Of URL Pharma For USD 800 Million 341

Takeda Completes Acquisition Of Intellikine For USD 310 Million 343

Takeda Pharmaceutical Co Ltd, Key Competitors 345

Takeda Pharmaceutical Co Ltd, Key Employees 346

Takeda Pharmaceutical Co Ltd, Other Locations 347

Takeda Pharmaceutical Co Ltd, Subsidiaries 347

Takeda Pharmaceutical Co Ltd, Joint Venture 354

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Takeda Pharmaceutical Co Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.